Osimertinib for the first-line treatment of EGFR-positive non-small cell lung cancer
- Authors: Reutova E.V1, Laktionov K.P1, Iudin D.I1, Neliubina L.A1, Gorokhova G.K2, Egorova A.V2
-
Affiliations:
- Blokhin National Medical Research Center of Oncology
- Pirogov Russian National Research Medical University
- Issue: Vol 21, No 3 (2019)
- Pages: 17-20
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/33508
- DOI: https://doi.org/10.26442/18151434.2019.3.190659
- ID: 33508
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Elena V Reutova
Blokhin National Medical Research Center of Oncology
Email: evreutova@rambler.ru
Cand. Sci. (Med.) Moscow, Russia
Konstantin P Laktionov
Blokhin National Medical Research Center of OncologyD. Sci. (Med.) Moscow, Russia
Denis I Iudin
Blokhin National Medical Research Center of OncologyD. Sci. (Med.) Moscow, Russia
Lidiia A Neliubina
Blokhin National Medical Research Center of OncologyD. Sci. (Med.) Moscow, Russia
Galina K Gorokhova
Pirogov Russian National Research Medical UniversityStudent Moscow, Russia
Angelina V Egorova
Pirogov Russian National Research Medical UniversityD. Sci. (Med.) Moscow, Russia
References
- Sharma S.V et al. Epidermal growth factor receptor mutations in lung cancer. Nature Rev Cancer 2007; 7: 169-81.
- Lynch T.J et al. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib. NEJM 2004; 350: 2129-39.
- Pao W et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
- Cheng et al. Molecular pathology of lung cancer: key to personalized medicine.Modern Pathology 2012; 25: 347-69.
- Tjulandin S et al. Prospective cohort study of clinical characteristics and management patterns for patients with non-small-cell lung cancer in the Russian Federation: EPICLIN-Lung CMRO 2015; 31 (6): 1117-27.
- Novello S et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27: v1-v27.
- Mitsudomi T et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-8.
- Yoshioka H et al. Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growt. J Clin Oncol 2014; 32: 8117.
- Mok T.S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-57.
- Fukuoka M et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011; 29: 2866-74.
- Zhou C et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-42.
- Zhou C et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL. CTONG-0802). Ann Oncol 2015; 26: 1877-83.
- Sequist L.V et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3327-34.
- Wu Y-L et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014; 15: 213-22.
- Yang J.C, Wu Y.L, Schuler M et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUXLung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015; 16: 141-51. doi: 10.1016/S1470-2045(14)71173-8
- Urata et al. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L. J Clin Oncol 2016; 34 (27): 3248-57.
- Paz-Ares L et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol 2017; 28 (2): 270-7.
- Soria J.C, Wu Y.L, Nakagawa K et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol 2015; 16: 990-8.
- Seto T, Kato T, Nishio M et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, Phase II study. Lancet Oncol 2014; 15: 1236-44.
- Saito H, Fukuhara T, Furuya N et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, Phase III trial. Lancet Oncol 2019; 20: 625-35.
- Инструкция по применению лекарственного препарата для медицинского применения осимертиниб от 11.05.2018. Регистрационное удостоверение ЛП-004492 от 18.10.2017.@@Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia osimertinib ot 11.05.2018. Registratsionnoe udostoverenie LP-004492 ot 18.10.2017 (in Russian).]
- Janne P.A et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015; 372: 1689-99.
- Colclough N et al. Preclinical comparison of the blood brain barrier (BBB) permeability of osimertinib (AZD9291) with other irreversible next generation EGFR TKIs. EJC December 2016; 69 (Suppl. 1): S28.
- Soria J.C, Ohe Y, Vansteenkiste J et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2018; 378 (2): 113-25. doi: 10.1056/NEJMoa1713137
- Ramalingam et al. Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis. Ann Oncol 2019; 30 (Suppl. 5): v851-v934.
- Портал Национального института рака США clinicaltrials.gov// Эл. ресурс: https://clinicaltrials.gov/ct2/ results?cond=&term=osimertinib&cntry=&state=&city=&dist= @@Portal Natsional'nogo instituta raka SShA clinicaltrials.gov// El. resurs: https://clinicaltrials.gov/ct2/results?cond=&term=osimertinib&cntry=&state=&city=&dist= (in Russian